Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
Public ClinicalTrials.gov record NCT03422003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized trial of hypofractionation (short-course) radiation therapy versus conventional radiation therapy in women who have undergone mastectomy and immediate breast reconstruction. The investigators will assess cosmetic and reconstruction outcomes, lymphedema, cancer status, side effects, and oncologic outcomes.
Study identification
- NCT ID
- NCT03422003
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2018 (Actual)
- Primary completion
- Oct 31, 2023 (Actual)
- Completion
- Apr 1, 2030 (Estimated)
- Last update posted
- Nov 1, 2024
2018 – 2030
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94115 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Vail Health | Edwards | Colorado | 81632 | — |
| Yale Cancer Center | New Haven | Connecticut | 06511 | — |
| Johns Hopkins Medicine | Washington D.C. | District of Columbia | 20016 | — |
| Eastern Maine Medical Center | Brewer | Maine | 04412 | — |
| Maine Medical Center | Scarborough | Maine | 04074 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital/North Shore Center for Outpatient Care | Danvers | Massachusetts | 01923 | — |
| Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center | Milford | Massachusetts | 01757 | — |
| Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| Lifespan/Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03422003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03422003 live on ClinicalTrials.gov.